announces that AstraZeneca has selected a candidate to progress in the Type 1 Diabetes (T1D) Treg cell therapy program. This is the first significant research milestone achieved under its 2023 ...

Type 1 Diabetes can be challenging for patients in terms of long-term disease management and impact on quality of life, with no options for disease-modifying therapies. Our ambition with this CAR-Treg ...

Astrazeneca plc has selected a candidate to progress under its type 1 diabetes regulatory T cell (Treg) therapy program with Quell Therapeutics Ltd. The company has exercised its exclusive option to ...

Privately-held UK Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has ...

Type 1 Diabetes can be challenging for patients in terms of long-term disease management and impact on quality of life, with no options for disease-modifying therapies. Our ambition with this CAR-Treg ...

程序性死亡受体-1（PD-1）的基因于1992年由日本科学家Honjo在小鼠中分离、鉴定，在经历细胞死亡的T细胞杂交瘤中发现，因此得名。PD-1与CTLA-4、CD28和KIRs的结构具有相似性，人们因此猜测PD-1的配体可能是B7或MHC I家族成员。在2000年和2001年，Honjo和Freeman先后发现了PD ...